After Vor Bio (VOR) announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg, Oppenheimer analyst Matthew Biegler noted that only two of 15 patients, versus two of 10 in the last update, relapsed and said engraftment data remains “encouraging.” Following the update, the firm reiterates its Outperform rating and $8 price target on Vor Bio shares.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VOR:
- Vor Bio announces updated data from Phase 1/2 VBP1-1 study
- Vor Biopharma Reports Promising Phase 1/2 Study Results
- Vor Bio price target lowered to $8 from $10 at Oppenheimer
- Vor Bio price target lowered to $14 from $22 at Baird
- Vor Biopharma Reports Q3 2024 Financial Results
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
